United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 22

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 22 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderAadi Bioscience · 41

Strongest available pathRoivant Sciences · +269.2%

Widest latest marginAadi Bioscience · -288.3%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1WHWK · Nasdaq

Aadi Bioscience

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Los Angeles$264.0M market cap

View full Companies Radar profile

41Cautious

Snapshot price$4.63as of page date

Monthly-close return-84.2%five-year window

FY2025 revenue$0.01BWhitehawk Therapeutics, Inc.

Net margin-288.3%FY2025

P/E snapshot-4.7xone ratio, not a verdict

Prism attention10.0%share across these five

Filing track recordRevenue, USD billions

+537.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 58.9%

52-week position77% through range

$1.76$5.50

News mentions395

Community mentions0partial coverage

U.S.-scope patents9

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability70/100
Market position7/100
Capital-event signal44/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2BOLT · Nasdaq

Bolt Biotherapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2015Redwood City, California$7.8M market cap

View full Companies Radar profile

41Cautious

Snapshot price$4.07as of page date

Monthly-close return-98.4%five-year window

FY2025 revenue$0.01BBolt Biotherapeutics, Inc.

Net margin-433.7%FY2025

P/E snapshot-0.2xone ratio, not a verdict

Prism attention11.1%share across these five

Filing track recordRevenue, USD billions

+510.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 57.2%

52-week position23% through range

$3.13$7.20

News mentions439

Community mentions1partial coverage

U.S.-scope patents257

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal59/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3RLYB · Nasdaq

Rallybio

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2018Farmington, Connecticut$88.6M market cap

View full Companies Radar profile

41Cautious

Snapshot price$16.69as of page date

Monthly-close return-88.1%five-year window

FY2025 revenue$0.00BRallybio Corp

Net margin-1046.4%FY2025

P/E snapshot2.1xone ratio, not a verdict

Prism attention14.1%share across these five

Filing track recordRevenue, USD billions

+43.0%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 43.0%

52-week position94% through range

$3.67$17.57

News mentions557

Community mentions1partial coverage

U.S.-scope patents36

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal53/100
Management stability90/100
Market position7/100
Capital-event signal43/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ROIV · Nasdaq

Roivant Sciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014New York City, New York$24.93B market cap

View full Companies Radar profile

40Cautious

Snapshot price$34.52as of page date

Monthly-close return+269.2%five-year window

FY2024 revenue$0.03BRoivant Sciences Ltd.

Net margin-592.0%FY2024

P/E snapshot-20.1xone ratio, not a verdict

Prism attention55.1%share across these five

Filing track recordRevenue, USD billions

-47.4%

FY2022–FY2024 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -27.5%

52-week position87% through range

$11.94$37.97

News mentions2.2K

Community mentions35partial coverage

U.S.-scope patents1

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal24/100
Management stability90/100
Market position21/100
Capital-event signal73/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 4 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TXMD · Nasdaq

TherapeuticsMD

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Boca Raton, Florida$25.1M market cap

View full Companies Radar profile

40Cautious

Snapshot price$2.17as of page date

Monthly-close return-94.1%five-year window

FY2023 revenue$0.00BTherapeuticsMD, Inc.

Net margin-380.8%FY2023

Prism attention9.7%share across these five

Filing track recordRevenue, USD billions

-94.6%

FY2019–FY2023 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2023 · CAGR -51.7%

52-week position60% through range

$0.99$2.95

News mentions384

Community mentions0partial coverage

U.S.-scope patents352

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal24/100
Management stability90/100
Market position12/100
Capital-event signal74/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Roivant Sciences

+269.2%

Aadi Bioscience

-84.2%

Rallybio

-88.1%

TherapeuticsMD

-94.1%

Bolt Biotherapeutics

-98.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Roivant Sciences

$0.03B

Bolt Biotherapeutics

$0.01B

Aadi Bioscience

$0.01B

TherapeuticsMD

$0.00B

Rallybio

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Aadi Bioscience

-288.3%

TherapeuticsMD

-380.8%

Bolt Biotherapeutics

-433.7%

Roivant Sciences

-592.0%

Rallybio

-1046.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Roivant Sciences

55.1%

Rallybio

14.1%

Bolt Biotherapeutics

11.1%

Aadi Bioscience

10.0%

TherapeuticsMD

9.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Roivant Sciences leads the conversation

It holds 55.1% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.03B.

Price path

Roivant Sciences leads the available price paths

Its monthly-close return is +269.2% for the five-year window. At the other end, Bolt Biotherapeutics is -98.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Aadi Bioscience has the widest latest margin

Its FY2025 net margin is -288.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Roivant Sciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -20.1x while its five-year window price return is +269.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ROIV

Roivant Sciences

2,187available Prism news records

Prism top themes

Price action & investor response

100

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.8%319 latest 12m vs 325 prior 12m

Machine-classified coverage tone

75.6% positive-5.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 45stock price 10stock surge 8stock indices 8market rally 8patent litigation 8angiogenesis inhibitors 7immunotherapy 6

Keyword tag occurrences in available Prism news records.

Coverage: 2014-12-23–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ROIV

Roivant Sciences

35 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 35 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

WHWK

Aadi Bioscience

through 2025-04-07

Earnings releases 7Business contracts 4M&A 1

2025-04-07
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aadi Bioscience $25.07 million 1.64 -$65.76 million ($2.35) -0.71
2025-02-27
M&A
Kraken’s prior offer to buy the entire company for what would likely amount to over $5 per share.
2024-12-20
Business contracts
Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs) ... Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million ...

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BOLT

Bolt Biotherapeutics

through 2026-02-06

Lawsuits 19Leadership changes 9Earnings releases 6

2026-02-06
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bolt Biotherapeutics $7.69 million 1.35 -$63.12 million ($22.38) -0.24 Radiopharm Theranostics $2.35 million 24.42 -$24.83 million N/A N/A
2024-09-03
Lawsuits
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) common shares between February 5, 2021 and May 14, 2024, that the defendants violated Federal Securities Laws.
2024-05-14
Leadership changes
Edith Perez moving to an advisory role

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RLYB

Rallybio

through 2026-03-03

Earnings releases 6Leadership changes 3M&A 3

2026-03-03
M&A
Rallybio Corporation (Nasdaq: RLYB) (Rallybio) and Candid Therapeutics, Inc. (Candid), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases, have announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction.
2025-11-06
Earnings releases
Revenue was $0.2 million for the third quarter of 2025, compared to $0.3 million for the same period in 2024. Net income was $16.0 million, or $0.36 per common share, for the third quarter of 2025 compared to a net loss of $11.5 million, or $0.26 per common share, for the same period in 2024.
2023-06-29
Leadership changes
Rallybio announced that Stephen Uden, M.D., Rallybio’s President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ROIV

Roivant Sciences

through 2025-12-18

Earnings releases 5Asset acquisitions 3Leadership changes 3M&A 3Listing / IPO 2

2025-12-18
M&A
Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.
2025-08-11
Earnings releases
Roivant reported that its revenue for the period was slightly under $2.2 billion, which was quite some distance down from the nearly $8 billion it reaped in the same quarter last year. The situation was hardly better on the bottom line, as the company flipped to a more than $223 million ($0.33 per share) generally accepted accounting principles (GAAP) net loss from the year-ago profit of $95 million.
2025-02-21
Leadership changes
Rakhi Kumar resigned from her roles as the Principal Accounting Officer of Roivant Sciences Ltd. and Chief Accounting Officer of its subsidiary, effective February 20, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TXMD

TherapeuticsMD

through 2025-11-13

Earnings releases 13M&A 2Listing / IPO 1

2025-11-13
Earnings releases
Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.
2025-02-14
Listing / IPO
Therapeuticsmd Inc. priced its $65 million underwritten public offering of common stock at $5.10 per share and a concurrent $20 million registered direct offering at the same price per share.
2023-01-03
M&A
TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited…

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 106–113. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Aadi Bioscience leads the readiness ranking

Its Prism readiness score is 41/100, the highest in this five-company comparison.

Open Aadi Bioscience in Companies Radar

Scale and margin leadership sit with Roivant Sciences and Aadi Bioscience

Roivant Sciences has the largest displayed latest revenue at $0.03B; Aadi Bioscience has the widest displayed latest margin at -288.3%.

Open Roivant Sciences in Companies Radar Open Aadi Bioscience in Companies Radar

Comparisons

Strongest versus weakest available price path

Roivant Sciences is +269.2% for its five-year window; Bolt Biotherapeutics is -98.4% for its five-year window.

Open Roivant Sciences in Companies Radar Open Bolt Biotherapeutics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.03B for Roivant Sciences to $0.00B for Rallybio. Entity and filing-period labels remain visible on the company cards.

Open Roivant Sciences in Companies Radar Open Rallybio in Companies Radar

Anomalies

Roivant Sciences has the widest attention-readiness rank gap

It ranks #1 by measured news attention (55.1%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Roivant Sciences in Companies Radar

Aadi Bioscience shows a price-operating divergence to inspect

Its displayed filing-revenue change is +537.9% while its available monthly-close return is -84.2%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Aadi Bioscience in Companies Radar

Explanations

Attention measures coverage volume, not quality

Roivant Sciences's 55.1% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Roivant Sciences in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Aadi Bioscience's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 41/100 score.

Open Aadi Bioscience in Companies Radar

Stress-test the largest divergence before forming a view

Compare Aadi Bioscience's profile with Roivant Sciences's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Aadi Bioscience in Companies Radar Open Roivant Sciences in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.